Background: Radiotherapy is an important and effective treatment for lung cancer. Some molecules can predict the effect of radiotherapy, but it is an invasive test that will cause trauma to patient. So the development of reliable non-invasive methods for predication of radiotherapy has become essential to guide therapy. Method: We initiated an analytical, observational, open, and retrospective study (ChiCTR1800014878) of 53 patients with stage III lung adenocarcinoma who were ready for radiotherapy. The performance status (PS) scores of the patients are all over 2. Blood and tumor tissue before treatment were collected to detect SDH5 concentration. We then evaluated the prognostic role of SDH5 expression in these patients. To further verify the effect of SDH5 on radiosensitivity, two mice models (orthotopic mice bearing lung cancer and SDH5 gene knock-out mice) were established and the internal mechanism between SDH5 and radiotherapy was explored. Result: The patients whose tumor shrink significantly one month after radiotherapy had lower expression of SDH5 in tumor, and loss of SDH5 expression correlated with down regulation of DNA-PKcs Thr2609 and ku86. More importantly, SDH5 can be directly detected in blood by qRT-PCR, and the result is consistent with that in tissue. And more exciting, patients with deficiency of SDH5 had longer PFS and OS after radiotherapy, and the results in blood and in tumor are consistent. To further verify the effect of SDH5 on radiosensitivity, in vivo experiments were carried out. In the orthotopic model, SDH5 knock down tumors showed higher radiation sensitivity with smaller volume. In SDH5 knock-out mice, lung epithelial cells exhibited elevated DNA damage after radiation. Moreover, our data indicated that SDH5 depletion causes P53 translocated from cytoplasm to nucleus, which enhances radiosensitivity of non-small cell lung cancer. Furthermore, consistent with in vivo data, the tumor growth was partially reversed when p53 was co-depleted with SDH5. Conclusion: In this experiment we found that SDH5 regulated radiosensitivity by P53 and it can be detected in tumor tissue. It is a suitable marker for predicting radiosensitivity. More than this, the expression of SDH5 can be directly measured by qRT-PCR in the blood, and it is consistent with that in the tumor tissue. This provides a novel noninvasive method for predicting the radiosensitivity of the patients unable to tolerant the biopsy.
Background: Radiotherapy is an important and effective treatment for lung cancer. Some molecules can predict the effect of radiotherapy, but it is an invasive test that will cause trauma to patient. So the development of reliable non-invasive methods for predication of radiotherapy has become essential to guide therapy. Method: We initiated an analytical, observational, open, and retrospective study (ChiCTR1800014878) of 53 patients with stage III lung adenocarcinoma who were ready for radiotherapy. The performance status (PS) scores of the patients are all over 2. Blood and tumor tissue before treatment were collected to detect SDH5 concentration. We then evaluated the prognostic role of SDH5 expression in these patients. To further verify the effect of SDH5 on radiosensitivity, two mice models (orthotopic mice bearing lung cancer and SDH5 gene knock-out mice) were established and the internal mechanism between SDH5 and radiotherapy was explored. Result: The patients whose tumor shrink significantly one month after radiotherapy had lower expression of SDH5 in tumor, and loss of SDH5 expression correlated with down regulation of DNA-PKcs Thr2609 and ku86. More importantly, SDH5 can be directly detected in blood by qRT-PCR, and the result is consistent with that in tissue. And more exciting, patients with deficiency of SDH5 had longer PFS and OS after radiotherapy, and the results in blood and in tumor are consistent. To further verify the effect of SDH5 on radiosensitivity, in vivo experiments were carried out. In the orthotopic model, SDH5 knock down tumors showed higher radiation sensitivity with smaller volume. In SDH5 knock-out mice, lung epithelial cells exhibited elevated DNA damage after radiation. Moreover, our data indicated that SDH5 depletion causes P53 translocated from cytoplasm to nucleus, which enhances radiosensitivity of non-small cell lung cancer. Furthermore, consistent with in vivo data, the tumor growth was partially reversed when p53 was co-depleted with SDH5. Conclusion: In this experiment we found that SDH5 regulated radiosensitivity by P53 and it can be detected in tumor tissue. It is a suitable marker for predicting radiosensitivity. More than this, the expression of SDH5 can be directly measured by qRT-PCR in the blood, and it is consistent with that in the tumor tissue. This provides a novel noninvasive method for predicting the radiosensitivity of the patients unable to tolerant the biopsy. Keywords: SDH5, non-invasive, Radiotherapy P3.01-63 Baseline Biomarkers for Outcome of Advanced NSCLC Patients Receiving Anti-PD1/PD-L1 Treatment-Data from a Chinese Population S. Lu Y. Yi Shanghai Chest Hospital, Shanghai/CN Background: Immune checkpoint inhibitor therapy has shown optimal efficacy in advanced non-small-cell lung cancer (NSCLC). However, the biomarkers of immunotherapy response are not well established. In the present study, we aimed to determine baseline prognostic factors associated with progression-free survival (PFS) in anti-PD1/PD-L1 treatment and to identify a predictive biomarker for immunotherapy response. Method: Data of 54 advanced NSCLC patients receiving anti-PD1/PD-L1 treatment were prospectively collected in Shanghai Chest Hospital from Dec. 2015 to May 2017. Clinical data included baseline routine blood examination and demographic characteristics of patients prior to immunotherapy. Systemic inflammatory biomarkers were obtained from routine blood tests to calculate leukocyte-to-lymphocyte ratio (LLR), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR) and systemic immune-inflammation index (SII, neutrophil Â platelet/lymphocyte). Receiver operating characteristic (ROC) and area under the curve (AUC) were used to identify the optimal cut-off value of LLR, NLR, PLR, LMR and SII for survival analysis. Endpoints were PFS and objective response rate (ORR) following anti-PD1/PD-L1 treatment. Univariate survival analysis for PFS was used by Kaplan-Meier method and statistical differences were determined by Log rank test. The Cox proportional hazards model was used for multivariable analysis. Result: A total of 54 cases were analyzed, with 38 treated with Atezolizumab and 16 treated with Nivolumab. Median PFS was 2.8±0.18 and 1.8±1.2 months, respectively (P ¼ 0.988). 44 patients received second-line anti-PD1/PD-L1 treatment and 10 patients underwent three-line or above. The median PFS of the two groups were 2.8±0.88 and 2.8±0.23 months, respectively, (P¼0.851). ROC and AUC identified LLR¼6.3, NLR¼4.5, PLR¼124.45, LMR¼3.4 and SII¼1066 as the best cut-off values. Univariate survival analysis showed that LLR, age, pathological type, neutrophil percentage, hemoglobin, platelet count, albumin, serum lactate dehydrogenase (LDH), NLR and SII were associated with PFS (P<0.05). Cox multivariate analysis showed that LLR (P¼0.003； HR 2.99；95%CI：1.45-6.17), albumin (P¼0.000；HR 8.11； 95% CI：2.63-25.06) and LDH (P¼0.000；HR 4.55；95%CI：2.13-9.73) were independent prognostic factors for PFS. For patients with favorable (1 IN 3 factors), (2 IN 3 factors) and (3 IN 3 factors) biomarker profile median PFS were 0.94, 1.63 and 8.17 months, respectively (P ¼0.000) . Conclusion: Blood markers predict survival in advanced NSCLC treated with immune checkpoint blockade. Our findings show that baseline LLR 6.3, normal serum levels of albumin and LDH were independently and advantageously associated with the PFS of patients receiving anti-PD1/PD-L1 treatment, and they may help identify patients with benefit from immune therapy. Keywords: anti-PD1/PD-L1 treatment, Biomarkers, Non-small-cell lung cancer Background: Activating RET-rearrangement has been discovered to play a crucial role in NSCLC tumorigenesis. However, the lack of specificity narrowed efficacy of multi-kinase inhibitors (MKIs) and the optimal treatment remains unknown. In this study, we compared chemotherapy, immunotherapy and MKIs in this group of patients. Method: We retrospectively evaluated the efficacy of these three treatments in advanced, RET-rearranged NSCLC patients between January 2013 and April 2018 at our institution. RET-rearrangements were assessed by Next-generation sequencing (NGS) or any of FISH, IHC, RT-PCR. Treatment data were collected after the patients had been diagnosed with RET-rearranged advanced NSCLC. Progression-free survival (PFS) was measured from treatment start to disease progression, all-cause mortality or last follow up. Median follow-up time was 5.1months. NGS was performed to assess somatic mutation of available samples. Result: A total of 30 patients with RET-rearrangement were investigated in this study. After the diagnosis, 15 patients, genetic profiles confirmed by NGS, received chemotherapy (n¼10), checkpoint-inhibitors (n¼7) and RET targeted MKI (n¼6) with evaluable response. Several patients take any two of these three treatments
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